Swedbank AB Raises Holdings in Eli Lilly and Company $LLY

Swedbank AB boosted its position in Eli Lilly and Company (NYSE:LLY) by 17.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,553,263 shares of the company’s stock after purchasing an additional 231,334 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Swedbank AB’s investment portfolio, making the stock its 10th largest holding. Swedbank AB’s holdings in Eli Lilly and Company were worth $1,185,140,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $27,000. Truvestments Capital LLC increased its position in Eli Lilly and Company by 30.8% during the 1st quarter. Truvestments Capital LLC now owns 880 shares of the company’s stock valued at $727,000 after buying an additional 207 shares in the last quarter. Finally, Orion Investment Co raised its stake in Eli Lilly and Company by 3.0% in the first quarter. Orion Investment Co now owns 476 shares of the company’s stock valued at $393,000 after buying an additional 14 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LLY shares. HSBC restated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Leerink Partners restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Wolfe Research raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Scotiabank began coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Stock Up 0.5%

NYSE:LLY opened at $1,077.06 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company’s fifty day moving average price is $981.27 and its 200-day moving average price is $839.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The firm has a market capitalization of $1.02 trillion, a P/E ratio of 52.69, a PEG ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.